Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
American Journal of Cancer Research|May 9, 2022
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaWei Teng, Chen-Chun Lin, Chung-Wei Su, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2024
Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational studyChao-Wei Lee, Hsing-Yu Chen, Ping-Han Tsai, et al.
Journal of Clinical and Translational Hepatology|March 11, 2026
Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched AnalysisYuan-Hung Kuo, Wei Teng, Yen-Hao Chen, et al.
Cancer Management and Research|November 17, 2022
Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG DiscontinuationPo-Ting Lin, Ming-Li Hsieh, Shih-Huan Su, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial ChemoembolizationPo-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
Cancer Medicine|December 5, 2022
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinomaChung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Iscience|June 22, 2026
Scanning Bessel beam microscopy with a protected and corrective objective for solvent-cleared large samplesChia-Ming Lee, Po-Yen Lin, Yu-Ting Tseng, et al.
Cancers|February 25, 2023
Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder CancerPo-Ting Lin, Wei-Kang Hung, Ying-Hsu Chang, et al.
The Oncologist|March 26, 2024
Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular CarcinomaChung-Wei Su, Wei Teng, Eric Yi-Liang Shen, et al.
American Journal of Cancer Research|September 11, 2023
Adding nutritional status to the original BCLC stage improves mortality prediction for hepatocellular carcinoma patients in HBV-endemic regionsYan-Ting Lin, Po-Ting Lin, Chen-Chun Lin, et al.
Pageof 7